MedTrace Logo

Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations

NCT04811001 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 170

Last updated 2023-02-21

No results posted yet for this study

Summary

The best drug sequencing of dacomitinib or osimertinib in patients with advanced or metastatic Epidermal Growth Factor Receptor (EGFR) mutation positive non-small-cell lung cancer (NSCLC) has not yet been determined. The study enables investigation of the efficacy of dacomitinib followed by or subsequent to osimertinib osimertinib in patients with classical or uncommon activating EGFR mutations. Efficacy of dacomitinib will be defined in patients with asymptomatic or controlled brain metastases, special population eligible in this clinical trial.

Conditions

Interventions

DRUG

Osimertinib

TAGRISSO 40 mg film-coated tablets TAGRISSO 80 mg film-coated tablets

DRUG

Dacomitinib

Vizimpro 15 mg film-coated tablets Vizimpro 30 mg film-coated tablets Vizimpro 45 mg film-coated tablets

Sponsors & Collaborators

  • Fondazione Ricerca Traslazionale

    lead OTHER

Principal Investigators

  • Alessandro Morabito, MD · Istituto Nazionale Tumori IRCCS Fondazione Pascale

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-12
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04811001 on ClinicalTrials.gov